Shaoxing Second Hospital Report issue

Academic/Hospital Phase 1 Phase 4

Organization Overview

First Clinical Trial
2012
NCT03880968
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Shaoxing Second Hospital

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 1)

Dwarfism, Pituitary (Phase 4)

Endocrine System Diseases (Phase 4)

Respiratory Distress Syndrome (Phase 1)

Respiratory Distress Syndrome, Newborn (Phase 1)

Spondylitis (Phase 4)

Spondylitis, Ankylosing (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 5